Design, synthesis and antihypertensive screening of novel pyridazine substituted s-triazin-2-imine/one/thione derivatives

References

• Williams AD, Lemke LT. Foye’s Principles of Medicinal Chemistry, in: David Troy (Ed.), fifth ed. Lippincott Williams & Wilkins, Baltimore, 2002, pp. 824–1195.
   Google Scholar
• Frank H, Heinisch G. In Pharmacological Active Pyridazines. Part 2. Progress in Medicinal Chemistry; Ellis, GP, Luscombe, DK Eds; Elsevier: Amsterdam, 1992; Vol. 29, p 141–168.
   Google Scholar
• Bristol JA, Sircar I, Moss WH, Evans DB, Weishmaan E. Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. J. Med. Chem. 1984;27:1099–1101.
   PubMed Web of Science ®Google Scholar
• Demirayak S, Karaburun AC, Beis R. Some pyrrole substituted aryl pyridazinone and phthalazinone derivatives and their antihypertensive activities. Eur. J. Med. Chem. 2004;39:1089–1095.
   PubMed Web of Science ®Google Scholar
• Smolyar NN, Yutilov YM, Gresko SV. Synthesis of 4-amino-6-(hetaryl)pyridazin-3-ones as analogs of pyridazine-based cardiotonic agents. Pharm. Chem. J. 2009;43:87–88.
   Google Scholar
• Unsal-Tan O, Ozden K, Rauk A, Balkan A. Synthesis and cyclooxygenase inhibitory activities of some N-acylhydrazone derivatives of isoxazolo[4,5-d]pyridazin-4(5H)-ones. Eur. J. Med. Chem. 2010;45(6):2345–2352.
   PubMedGoogle Scholar
• Mirzoeva S, Sawkar A, Zasadzki M, Guo L, Velentza AV, Dunlap V, Bourguignon JJ. Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound. J. Med. Chem. 2002;45:563–566.
   PubMedGoogle Scholar
• Sotelo E, Coelho A, Ravina E., Pyridazines. Part 34: Retro-ene-assisted palladium-catalyzed synthesis of 4,5-disubstituted-3(2H)-pyridazinones. Tetrahedron Lett. 2003;44:4459–4462.
   Web of Science ®Google Scholar
• Foks H, Wisterowicz K, Miszke A, Brozewicz K, Wisnlewska K, Szponar MD. Synthesis, fungicidal and antibacterial activity of new pyridazine derivatives. Heterocycles. 2009;78:961–975.
   Google Scholar
• Kaizerman J, Lucas B, McMinn DL, Zamboni R. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signaling. PCT Int. Appl. 2009, WO 2009035568.
   Google Scholar
• Ishida A, Honma K, Yato M, Nishiyama S, Okumura F. The syntheses of several heterocyclic skeletons of pyridazine. Eur. Pat. Appl. 1995, EP 661273.
   Google Scholar
• Monge A, Parrado P, Font M, Alvarez EF. Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinotriazino[4,5-a]indole, and related compounds. J. Med. Chem. 1987;30(6):1029–1035.
   PubMedGoogle Scholar
• Akahane A, Katayama H, Mitsunaga T, Kato T, Kinoshita T, Kita Y, Kusunoki T, Terai T, Yoshida K, Shiokawa Y. Discovery of 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinebutanoic acid (FK 838): A novel non-xanthine adenosine A1 receptor antagonist with potent diuretic activity. J. Med. Chem. 1999;42(5):779–783.
   PubMedGoogle Scholar
• Livermone DGH, Bethell RC, Cammack N, Hancock AP, Hann MM, Green DVS, Lamont RB, Noble SA, Orr DC. Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-b]pyridazines. J. Med. Chem. 1993;36:3784–3794.
   PubMed Web of Science ®Google Scholar
• Combs DW, Rampulla MS, Bell SC, Klaubert DH, Tobia AJ, Falotico R, Haertlein B, Weiss CL, Moore JB. 6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents. J. Med. Chem. 1990;33(1):380–386.
   PubMedGoogle Scholar
• Robertson DW, Jones ND, Krushinski JH, Pollock GD, Swartzendruber JK, Hayes JS. Molecular structure of the dihydropyridazinone cardiotonic 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one, a potent inhibitor of cyclic AMP phosphodiesterase. J. Med. Chem. 1987;30(4):623–627.
   PubMedGoogle Scholar
• Archan S, Toller W. Levosimendan: current status and future prospects. Curr. Opin. Anesthesiol 2008;21(1):78–84.
   PubMedGoogle Scholar
• Thota S, Bansal R. Synthesis of new pyridazinone derivatives as platelet aggregation inhibitors. Med. Chem. Res. 2010;19:808-816. DOI: 10.1007/s00044-009-9232-6.
   Google Scholar
• Schade FU, Schudt C. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur. J. Pharmacol. 1993;230(1):9–14.
   PubMedGoogle Scholar
• Sotelo E, Fraiz N, Yanez M, Terrades V, Laguna R, Cano E, Ravina E., Pyridazines. Part XXIX: synthesis and platelet aggregation inhibition activity of 5-substituted-6-phenyl-3(2H)-pyridazinones. Novel aspects of their biological actions. Bioorg. Med. Chem. 2002;10:2873–2882.
   PubMed Web of Science ®Google Scholar
• Gajare AS, Shingare MS. Synthesis of 2,4-Diarylamino-6-(3′,5′,6′-trichloropyridin-2′-yl)oxy Triazine and Its Herbicidal Activity. Ind. J. Chem. 1998;37B:510–513.
   Google Scholar
• Khan MSY, Siddiqui AA. Pyridazinone derivatives: A potent anti-inflammatory agents. Ind. J. Chem. 2000;39B:614–620.
   Google Scholar
• Siddiqui AA, Ahamad SR, Mira MS, Hussain SA, Raish M, Kaur R. Synthesis and in-vitro antifungal activity of 6-substituted-phenyl-2- {[(4′-substituted phenyl-5′-thioxo)-1,2,4-triazol-3-yl]-methyl}-2,3,4,5-tetrahydropyridazin-3-one derivatives. Acta. Pol. Pharm. 2008;65 (2):223–228.
   PubMedGoogle Scholar
• Krakoff LR, Selvadurai R, Sytter E. Effect of methylprednisolone upon arterial pressure and the renin angiotensin system in the rat. Am. J. Physiol. 1975;228:613–617.
   PubMed Web of Science ®Google Scholar
• Borchard RE, Barnes CD, Eltherington LG. Drug Dosage in Laboratory Animals: A Handbook, third ed. The Telford Press Inc., New Jersey, 1991.
   Google Scholar